Incannex reports first patient dosed in Phase 2 IHL-42X study
Incannex Healthcare said its DReAMzz Phase 2 IHL-42X study has dosed the first patient and that a U.S. patent was granted. The company also said it holds about $70 million in cash.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Incannex (IXHL) reports first patient dosed in DReAMzz Phase 2 study
Incannex announces the first patient is dosed in its DReAMzz Phase 2 study of IHL-42X; the source provides no additional dosing schedule, results, or catalyst details.